Neurelis logo

Neurelis

Challenger

Neuroscience pharma commercializing VALTOCO (diazepam nasal spray) for seizure clusters. ~$295-300M estimated net sales in 2025; 30%+ EBITDA margin; no bank debt.

Best for: Neurology / Pharmaceuticals
Life Sciences & BioTechNeurology / PharmaceuticalsWebsiteUpdated May 2026

Company Overview

Neurelis is a private neuroscience-focused pharmaceutical company dedicated to developing and commercializing therapies for epilepsy and neurological disorders. Its lead commercial product, VALTOCO (diazepam nasal spray), is an FDA-approved treatment for acute seizure clusters in patients aged two and older — a label expansion to children ages two to five was approved in April 2025. The company reported estimated net sales of $295–300 million for 2025, more than doubling 2024 revenue, with an EBITDA margin exceeding 30% and a debt-free balance sheet holding $175M+ in cash. VALTOCO''s Orange Book patent portfolio now includes six listed patents, extending exclusivity to October 2032. Neurelis is using this commercial momentum to advance its CNS pipeline and pursue additional products.

Curated content • Fact-checked and verified

Key Differentiators

Strong Challenger

Neurelis is an established challenger with significant market presence and competitive offerings in Life Sciences & BioTech.

Frequently Asked Questions

Similar Brands

BioNTech logo

BioNTech

Life Sciences & BioTech
B2bGlobalPublicEnterpriseHealthtechManufacturingPlatform

BioNTech SE was founded in 2008 in Mainz, Germany by Ugur Sahin, Ozlem Tureci, and Christoph Huber with a mission to harness the immune system for individualized cancer treatment. The company pioneere

Genentech logo

Genentech

Life Sciences & BioTech
B2bGlobalEnterprisePublicHealthtechManufacturingFortune500

Genentech was founded in 1976 in South San Francisco by Herbert Boyer and Robert Swanson, becoming the first company to produce human insulin using recombinant DNA technology and essentially launching

Illumina logo

Illumina

Life Sciences & BioTech
B2bGlobalPublicEnterpriseHealthtechAnalyticsHardwarePlatformFortune500

Illumina was founded in 1998 in San Diego and has grown into the undisputed leader in next-generation sequencing (NGS), with approximately 80% global market share across research and clinical applicat

Regeneron logo

Regeneron

Life Sciences & BioTech
B2bGlobalPublicEnterpriseHealthtechManufacturingFortune500

Regeneron Pharmaceuticals was founded in 1988 in Tarrytown, New York by Leonard Schleifer and George Yancopoulos. The company built its reputation on the Velocimmune platform—a proprietary humanized m

Cradle logo

Cradle

Life Sciences & BioTech
HealthtechSaasNorth AmericaB2b

Cradle is a protein design platform using AI to help biotechnology and pharmaceutical companies engineer better proteins — enzymes, antibodies, and therapeutic proteins — with improved stability, acti

Vivtex logo

Vivtex

BioTech
HealthtechB2b

Vivtex is an MIT Langer Laboratory spinout that has developed a drug delivery platform enabling oral administration of biologics — proteins, peptides, and other large molecules — that have historicall

Compare Neurelis with Competitors

Side-by-side AI visibility scores, platform breakdown, and market position.

For Neurelis

Claim This Profile

Are you from Neurelis? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.

Claim Neurelis Profile →
For competitors & analysts

Track AI Visibility in Real Time

Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Neurelis vs competitors. Get alerts when AI recommendations shift.

Start Free Tracking →